About: Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach
Creator	Kotanidou, Anastasia Argentos, Stylianos Baou, Katerina Karakatsani, Anna Kagouridis, Konstantinos Kolilekas, Likurgos Malagari, Katerina Manali, Effrosyni Papaioannou, Andriana Papiris, Spyros Roussou, Aneza Triantafillidou, Christina
Source	PMC
abstract	BACKGROUND: Idiopathic pulmonary fibrosis acute exacerbation (IPF-AE) constitutes IPF’s most devastating event, representing the unexpected superimposition of diffuse alveolar damage of unknown etiology. Guidelines recommend high-dose steroids treatment despite unproven benefit. We hypothesized that previous immunosuppression and the administration of high-dose steroids adversely affect IPF-AE outcome. METHODS: We studied all consecutive patients hospitalized in our department for IPF deterioration from 2007 to June 2013. Our protocol consisted of immediate cessation of immunosuppression (if any), best supportive care, broad-spectrum antimicrobials and thorough evaluation to detect reversible causes of deterioration. Patients were followed-up for survival; post-discharge none received immunosuppression. RESULTS: Twenty-four out of 85 admissions (28 %) fulfilled IPF-AE criteria. IPF-AE were analyzed both as unique events and as unique patients. As unique events 50 % survived; 3 out of 12 (25 %) in the group previously treated with immunosuppression whereas nine out of 12 (75 %) in the group not receiving immunosuppression (p = 0.041). As unique patients 35.3 % survived; 3 out of 6 (50 %) in the never treated group whereas three out of 11 (27.3 %) in the group receiving immunosuppression (p = 0.685). The history of immunosuppression significantly and adversely influenced survival (p = 0.035). Survival was greater in the never treated group compared to the immunosuppressed patients (p = 0.022). Post-discharge, our IPF-AE survivors had an 83 % 1-year survival. CONCLUSIONS: By applying the above mentioned protocol half of our patients survived. The history of immunosuppression before IPF-AE adversely influences survival. Avoiding steroids in IPF patients may favor the natural history of the disease even at the moment of its most devastating event.
has issue date	2015-12-14(xsd:dateTime)
bibo:doi	10.1186/s12890-015-0146-4
bibo:pmid	26666385
has license	cc-by
sha1sum (hex)	a3e7f6f86be44d7e5cad642fc7ac1c22308b44e8
schema:url	https://doi.org/10.1186/s12890-015-0146-4
resource representing a document's title	Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach
has PubMed Central identifier	PMC4678631
has PubMed identifier	26666385
schema:publication	BMC Pulm Med
resource representing a document's body	covid:a3e7f6f86be44d7e5cad642fc7ac1c22308b44e8#body_text
is schema:about of	named entity 'survival' named entity 'protocol' named entity 'representing' named entity 'receiving' named entity 'receiving' named entity 'Guidelines' named entity 'hypothesized' named entity 'events' named entity 'IPF' named entity '0.035' named entity 'SURVIVAL' named entity 'FOLLOWED' named entity 'IMMUNOSUPPRESSION' named entity 'RESULTS' named entity 'STEROIDS' named entity 'IMMUNOSUPPRESSED PATIENTS' named entity '2007' named entity 'received' named entity 'Our' named entity 'etiology' named entity 'survival' named entity 'group' named entity 'compared' named entity 'immunosuppression' named entity 'The' named entity 'immunosuppression' named entity 'treated' named entity 'steroids' named entity 'group' named entity 'events' named entity 'history' named entity 'cessation' named entity 'steroids' named entity 'IPF' named entity 'immunosuppression' named entity 'adversely affect' named entity 'IPF' named entity 'diffuse alveolar damage' named entity 'immunosuppression' named entity 'natural history of the disease' named entity 'patients' named entity 'lung' named entity 'IPF' named entity 'IPF' named entity 'sputum' named entity 'IPF' named entity 'lymphocytes' named entity 'acute respiratory distress syndrome' named entity 'acute exacerbation' named entity 'antimicrobials' named entity 'Chlamydophila Pneumoniae' named entity 'methotrexate' named entity 'TLC' named entity 'immunosuppressive therapy' named entity 'Heart failure' named entity 'diffusing capacity' named entity 'steroids' named entity 'IPF' named entity 'invasive mechanical ventilation' named entity 'IPF' named entity 'supportive care' named entity 'pulmonary embolism' named entity 'IPF' named entity 'pulmonary hypertension' named entity 'pharmacological treatment' named entity 'pneumonia' named entity 'IPF' named entity 'Altrincham' named entity 'lung injuries' named entity 'antimicrobials'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software